Primary Biliary Cholangitis (PBC) is a chronic autoimmune condition that significantly impacts the liver over time. Although many patients remain stable with early treatment, others progress toward liver failure. Consequently, clinicians must understand the substantial economic burden associated with advanced disease. A recent retrospective study has quantified Primary Biliary Cholangitis costs, focusing specifically on hepatic decompensation and liver transplantation events.

Analyzing Primary Biliary Cholangitis Costs in Advanced Disease

Researchers analyzed data from a large administrative database to evaluate these medical expenses. Specifically, they looked at two cohorts: patients with hepatic decompensation and those undergoing liver transplantation. The results were striking. For hepatic decompensation events, the mean cost per event reached $63,612.09. However, this figure rose significantly to $116,424.25 when a readmission occurred within 30 days. In contrast, events without readmission averaged roughly $43,405.

Furthermore, the liver transplantation cohort faced even higher financial demands. The total mean cost per patient for a transplant was approximately $328,336.60. Notably, the hospitalization for the transplant itself accounted for the largest share of the expense, averaging $226,908.70 per patient. These findings highlight that proactive patient management is vital. By slowing disease progression, healthcare providers may help to mitigate the heavy economic burden of PBC-related complications.

Frequently Asked Questions

How does 30-day readmission affect Primary Biliary Cholangitis costs?

Readmissions significantly inflate the cost of care for hepatic decompensation. In this study, events requiring readmission within 30 days were nearly three times more expensive than those that did not require a return to the hospital.

What is the primary driver of cost in PBC transplantation?

The actual hospitalization for the transplant procedure is the most expensive component. It averages over $226,000, which covers the surgery and immediate post-operative care.

Can early management reduce the economic impact of PBC?

Yes, appropriate management to prevent disease progression can help avoid high-cost events like decompensation and the need for liver transplantation.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Gish RG et al. Cost of hepatic decompensation and liver transplantation events in primary biliary cholangitis: a retrospective observational study. J Comp Eff Res. 2026 Feb 16. doi: 10.57264/cer-2025-0110. PMID: 41693640.

Lammers EN et al. Healthcare resource utilization and cost burden in patients with primary biliary cholangitis. Value Health. 2024;27(6):S1.

Harms MH et al. Economic burden of primary biliary cholangitis by line of therapy. J Comp Eff Res. 2025 Dec 4. doi: 10.57264/cer-2025-0012.